multiQure stock reports a PLN 100,000 director purchase

Published on 10/08/2026 at 07:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

multiQure stock follows a PLN 100,000 director purchase disclosed on October 5, 2026. Its half-year loss reached PLN 150.240 million.

Pure Biologics, PLPRBLG00010, Illustration mit AI erstellt.

multiQure stock (ISIN PLPRBLG00010) was last at PLN 1.568 on the GPW on October 7, 2026, up 3.21 percent. The immediate company signal was a PLN 100,000 share purchase by Chief Executive Filip Jelen, disclosed in a report dated October 5, 2026.

Director purchase sets the latest signal

According to Parkiet on October 5, 2026, multiQure received notification that Jelen bought company shares in a transaction dated October 2, 2026. MamBiznes.pl reported that the purchase totaled PLN 100,000 and linked it to preparations for the companys first experimental RNAi therapy application.

The purchase came after multiQure had signed a letter of intent with Mazowiecki Hospital Bródnowski and Professor Miroslaw Zabek for preparations connected with experimental treatment of Huntingtons disease. The September 28, 2026 report also stated that regulatory, technological and clinical preparations must be completed before treatment can begin.

Half year loss reaches PLN 150.240 million

The half-year filing for January through June 2026 reported PLN 968,000 in operating revenue, compared with PLN 2.462 million in operating costs. According to Parkiet, the net loss reached PLN 150.240 million, versus PLN 6.057 million in the first half of 2025, while operating cash flow was negative PLN 4.047 million.

The filing also showed PLN negative 12.59 earnings per share for the first half of 2026, compared with PLN negative 1.51 a year earlier. That contrast makes clinical execution and financing capacity the central issues behind the insider purchase, rather than current revenue generation.

Clinical timetable points to November 16

The companys investor calendar lists October 17, 2026, as the start of the closed period before its quarterly report and November 16, 2026, as the publication date for the Q3 2026 report, according to multiQure. The dates give investors a defined checkpoint for cash use, development progress and the next operating update.

Stock remains below the yearly high

At PLN 1.568 on the GPW on October 7, 2026 at 5:04 p.m. CEST, multiQure was 76.87 percent below its 52-week high of PLN 6.7800 and 14.45 percent above its 52-week low of PLN 1.3700. The range puts the latest quote closer to the yearly low than the yearly high.